## Synephrine hydrochloride

MedChemExpress

®

Cat. No.:	HY-N0132A	
CAS No.:	5985-28-4	ОН <sub>П</sub>
Molecular Formula:	C <sub>9</sub> H <sub>14</sub> CINO <sub>2</sub>	$\sim$ $\downarrow$ $N_{\sim}$
Molecular Weight:	203.67	
Target:	Adrenergic Receptor; Endogenous Metabolite	HO
Pathway:	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease	
Storage:	4°C, sealed storage, away from moisture	HCI
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

	<b>U</b>	DMSO : ≥ 52 mg/mL (255.31 mM) * "≥" means soluble, but saturation unknown.				
		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	4.9099 mL	24.5495 mL	49.0990 mL	
		5 mM	0.9820 mL	4.9099 mL	9.8198 mL	
		10 mM	0.4910 mL	2.4550 mL	4.9099 mL	

BIOLOGICAL ACTIV	ІТҮ	
Description		hydrochloride, an alkaloid, is an α-adrenergic and β-adrenergic agonist derived from the Citrus hydrochloride is a sympathomimetic compound and can be used for weight $loss^{[1][2]}$ .
IC <sub>50</sub> & Target	$\beta$ adrenergic receptor	
In Vivo	and BDL rats. The porta reduced, while mean an of Synephrine <sup>[2]</sup> .	ral gavage; for 8 days; PVL and BDL rats) significantly ameliorates the hyperdynamic state in both PVL l venous pressure in PVL and BDL rats, portal tributary blood flow and cardiac index are significantly terial pressure and systemic as well as portal territory vascular resistance are enhanced by treatment ntly confirmed the accuracy of these methods. They are for reference only. Portal vein ligation (PVL) or bile duct ligation (BDL) rats <sup>[2]</sup>
	Dosage:	1 mg/kg per 12 hours

Administration:	Oral gavage; for 8 days
Result:	The portal venous pressure in PVL and BDL rats, portal tributary blood flow and cardia
	index were significantly reduced, while mean arterial pressure and systemic as well as
	portal territory vascular resistance were enhanced.

## REFERENCES

[1]. Thomas JE, et al. STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: a case report and review of the literature. Tex Heart Inst J. 2009;36(6):586-90.

[2]. Huang YT, et al. Hemodynamic effects of synephrine treatment in portal hypertensive rats. Jpn J Pharmacol. 2001 Feb;85(2):183-8.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA